



# GLAND PHARMA LIMITED

January 22, 2022

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

**Sub: Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 2022**

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed copies of the newspaper advertisement pertaining to Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2021. The advertisements were published in English and Telugu newspapers.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



**Sampath Kumar Pallerlamudi**  
Company Secretary

Encl: As mentioned above

**Regd. Office:**

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads  
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal  
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India  
Tel: +91-40-30510999 Fax: +91-40-30510800

**Corporate Office:**

Plot No. 11 & 84, TSIC Phase: IV  
Pashamylaram (V), Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India  
Tel: +91-8455-699999



## GLAND PHARMA LIMITED

Corporate Identification Number: L24239TG1978PLC002276  
 Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally,  
 Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India  
 Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

### EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in Millions)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	34,628.76
Profit before tax	3,655.63	4,006.65	2,732.38	12,380.68	9,858.67	13,348.10
Profit for the period/year	2,730.29	3,020.81	2,041.07	9,257.62	7,365.54	9,969.63
Total comprehensive income (after taxes)	2,739.22	3,012.79	2,048.93	9,255.77	7,353.36	9,960.91
Paid up equity share capital (Face value of ₹/- each)	164.30	164.23	163.28	164.30	163.28	163.59
Other equity						58,868.83
Earnings per equity share (Face value of ₹/- each): (Not annualised for the quarter and nine months ended)						
Basic (₹)	16.62	18.37	12.83	56.41	47.12	63.07
Diluted (₹)	16.62	18.37	12.82	56.41	47.10	62.99

Additional information on Standalone Financial Results is as follows:

(₹ in Millions)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	34,628.76
Profit before tax	3,659.18	4,007.04	2,732.38	12,384.85	9,858.67	13,348.52
Profit for the period/year	2,733.84	3,021.20	2,041.07	9,261.79	7,365.54	9,970.05


**Notes:**

- The Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021 ("Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 21, 2022.
- The public issue net proceeds of the Initial Public Offer are being utilised as per the objects stated in the Prospectus of the Company. Accordingly we don't have any deviations or variations to be reported in the utilisation of the public issue proceeds for the quarter ended December 31, 2021.
- The above is an extract of the detailed format of quarter and nine months ended Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) and on the website of the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and BSE Limited ([www.bseindia.com](http://www.bseindia.com)).

For and on behalf of the Board  
**Gland Pharma Limited**  
 Sd/-  
**Srinivas Sadu**  
 Managing Director and CEO  
 DIN No. 06900659

Hyderabad  
 January 21, 2022

**Financial Express- January 22, 2022**

 <b>GLAND PHARMA LIMITED</b> Corporate Identification Number: L24239TG1978PLC002276 Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally, Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com						
<b>EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS                      FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021</b>						
(₹ in Millions)						
Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	34,628.76
Profit before tax	3,655.63	4,006.65	2,732.38	12,380.68	9,858.67	13,348.10
Profit for the period/year	2,730.29	3,020.81	2,041.07	9,257.62	7,365.54	9,969.63
Total comprehensive income (after taxes)	2,739.22	3,012.79	2,048.93	9,255.77	7,353.36	9,960.91
Paid up equity share capital (Face value of ₹/- each)	164.30	164.23	163.28	164.30	163.28	163.59
Other equity						58,868.83
Earnings per equity share (Face value of ₹/- each): (Not annualised for the quarter and nine months ended)						
Basic (₹)	16.62	18.37	12.83	56.41	47.12	63.07
Diluted (₹)	16.62	18.37	12.82	56.41	47.10	62.99
<b>Additional information on Standalone Financial Results is as follows:</b>						
(₹ in Millions)						
Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	34,628.76
Profit before tax	3,659.18	4,007.04	2,732.38	12,384.85	9,858.67	13,348.52
Profit for the period/year	2,733.84	3,021.20	2,041.07	9,261.79	7,365.54	9,970.05
<b>Notes:</b>						
1. The Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021 ("Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 21, 2022.						
2. The public issue net proceeds of the Initial Public Offer are being utilised as per the objects stated in the Prospectus of the Company. Accordingly we don't have any deviations or variations to be reported in the utilisation of the public issue proceeds for the quarter ended December 31, 2021.						
3. The above is an extract of the detailed format of quarter and nine months ended Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Company's website ( <a href="http://www.glandpharma.com">www.glandpharma.com</a> ) and on the website of the National Stock Exchange of India Limited ( <a href="http://www.nseindia.com">www.nseindia.com</a> ) and BSE Limited ( <a href="http://www.bseindia.com">www.bseindia.com</a> ).						
For and on behalf of the Board <b>Gland Pharma Limited</b> Sd/- Srinivas Sadu Managing Director and CEO DIN No. 06900659						
Hyderabad January 21, 2022						



Andhra Prabha- January 22, 2022

శనివారం 22 జనవరి 2022

ఆంధ్రప్రదేశ్

హైదరాబాద్ | 5

### GLAND PHARMA LIMITED

Corporate Identification Number: L24239TG1978PLC002276  
Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally,  
Dundigal - Gandhi Maisamma (M), Medchal-Malkajigiri District, Hyderabad 500 043, Telangana, India  
Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

**31 డిసెంబరు, 2021లో ముగిసిన త్రైమాసిక మరియు తొమ్మిది నెలల కొరకు ఆడిట్ చేయని కన్సాలిడేటెడ్ ఆర్థిక ఫలితాల యొక్క సారాంశం**

వివరములు	ముగిసిన త్రైమాసికం			ముగిసిన తొమ్మిది నెలలు		ముగిసిన సంవత్సరం
	31-డిసెంబరు-21 (ఆడిట్ చేయబడింది)	30-సెప్టెంబరు-21 (ఆడిట్ చేయబడింది)	31-డిసెంబరు-20 (ఆడిట్ చేయబడింది)	31-డిసెంబరు-21 (ఆడిట్ చేయబడింది)	31-డిసెంబరు-20 (ఆడిట్ చేయబడింది)	31-మార్చి-21 (ఆడిట్ చేయబడింది)
అప్పుకావాలి మరియు అదాయం	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	34,628.76
పన్నుకావాలి అదాయం	3,655.63	4,006.65	2,732.38	12,380.68	9,858.67	13,348.10
అలాం / సంవత్సరం కొరకు అదాయం	2,730.29	3,020.81	2,041.07	9,257.62	7,365.54	9,969.63
మొత్తం పన్ను అదాయం (మొత్తం అదాయం)	2,739.22	3,012.79	2,048.93	9,255.77	7,353.36	9,960.91
చెల్లించిన కుప్పకీ వాటా మూలధనం (ముఖ రుపాయ్ ₹ 1/- చొప్పున)	164.30	164.23	163.28	164.30	163.28	163.59
అలాం కుప్పకీ వాటా మూలధనం (ముఖ రుపాయ్ ₹ 1/- చొప్పున)						58,868.83
ముందు తొమ్మిది నెలల కొరకు అదాయం (ముఖ రుపాయ్ ₹ 1/- చొప్పున)	16.62	18.37	12.83	56.41	47.12	63.07
కొరకు (₹)	16.62	18.37	12.82	56.41	47.10	62.99

**స్టాండ్ లాలోడ్ ఆర్థిక ఫలితాలపై అదనపు సమాచారం దిగువ వివరించబడింది.**

వివరములు	ముగిసిన త్రైమాసికం			ముగిసిన తొమ్మిది నెలలు		ముగిసిన సంవత్సరం
	31-డిసెంబరు-21 (ఆడిట్ చేయబడింది)	30-సెప్టెంబరు-21 (ఆడిట్ చేయబడింది)	31-డిసెంబరు-20 (ఆడిట్ చేయబడింది)	31-డిసెంబరు-21 (ఆడిట్ చేయబడింది)	31-డిసెంబరు-20 (ఆడిట్ చేయబడింది)	31-మార్చి-21 (ఆడిట్ చేయబడింది)
అప్పుకావాలి మరియు అదాయం	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	34,628.76
పన్నుకావాలి అదాయం	3,659.18	4,007.04	2,732.38	12,384.85	9,858.67	13,348.52
అలాం / సంవత్సరం కొరకు అదాయం	2,733.84	3,021.20	2,041.07	9,261.79	7,365.54	9,970.05

**గమనిక:**

- కంపెనీ ("ఆడిట్ చేయని కన్సాలిడేటెడ్ ఆర్థిక ఫలితాలు") యొక్క డిసెంబరు 31, 2021లో ముగిసిన త్రైమాసిక మరియు తొమ్మిది నెలల కొరకు ఆడిట్ చేయని కన్సాలిడేటెడ్ ఆర్థిక ఫలితాలపై ఆడిట్ కమిటీని నియోజ్ఞించబడినది మరియు జనవరి 21, 2022లో అలాం సమావేశం ద్వారా ప్రకటించబడింది.
- కంపెనీ యొక్క ఫైనాన్షియల్ తెలివితేటల అన్ని అంశాలను అనుబంధ వార్షిక ఆఫర్ డాక్యుమెంట్ ద్వారా సరైన ప్రకటనలు ఉపయోగించబడినవి. అందువల్లగా డిసెంబరు 31, 2021లో ముగిసిన త్రైమాసికం కొరకు వార్షిక ఆఫర్ డాక్యుమెంట్ యొక్క వివరాలను ఉపయోగించుకోవాలి. ఏమని దీనియొక్క లేదా కృత్యానికే మేము తెలుపబడినవి అవ్వవచ్చు.
- నేత (గ్లోబల్ ఆఫ్ఫీస్) మరియు డిస్ట్రిబ్యూట్ (అమ్మకం) రెగ్యులేషన్స్, 2015 యొక్క సెక్షన్ 33 క్రింద స్టాక్ ఎక్స్చేంజ్ ద్వారా చేయబడిన త్రైమాసిక మరియు తొమ్మిది నెలల కొరకు ఆడిట్ చేయని ఆర్థిక ఫలితాల యొక్క సమాఖా యొక్క సారాంశం పైన వివరించబడింది. ఆడిట్ చేయని ఆర్థిక ఫలితాల యొక్క పూర్తి సమాఖా కంపెనీ యొక్క వెబ్సైట్ ([www.glandpharma.com](http://www.glandpharma.com)) మరియు నేషనల్ స్టాక్ ఎక్స్చేంజ్ లో ఇంటర్నెట్ డిమాండ్ యొక్క వెబ్సైట్ ([www.nseindia.com](http://www.nseindia.com)) మరియు బీసీఎస్ డిమాండ్ ([www.bseindia.com](http://www.bseindia.com)) పై కూడా పొందవచ్చు.

Hyderabad  
January 21, 2022

For and on behalf of the Board  
**Gland Pharma Limited**  
Sd/-  
**Srinivas Sadu**  
**Managing Director and CEO**  
DIN No. 06900659